Merck Covid antiviral pill did not cut hospitalisation risk, study finds
Merck’s Covid-19 antiviral pill failed to show it can lower the risks of hospitalisation and death among adults at higher...
Merck’s Covid-19 antiviral pill failed to show it can lower the risks of hospitalisation and death among adults at higher...
SYDNEY, Oct 7 (Reuters) - BioNTech SE, the German biotech that developed a widely used COVID-19 vaccine with Pfizer Inc,...
This video can not be playedTo play this video you need to enable JavaScript in your browser.By Stephen McDonellBBC News,...
TOKYO, Oct 5 (Reuters) - Japan's services sector activity growth posted a small expansion in September as demand recovered on...
A 35-year-old acquaintance drops dead from a hemorrhagic stroke. A friend in her 40s, and another in his 70s, experience...
Oct 6 (Reuters) - A rebound of COVID-19 symptoms in some patients after taking Pfizer's antiviral Paxlovid may be related...
BERLIN, Oct 6 (Reuters) - The German government expects Europe's largest economy to slide into recession next year, contracting 0.4%...
BOSTON - There's no doubt that the COVID vaccines continue to save lives but a woefully low number of people...
Go Nakamura/Getty Images A new study published this week by the National Bureau of Economic Research found the gap between...
mRNA COVID-19 vaccines might do more harm than good Inadequate support: Malhotra’s claim that COVID-19 vaccines might do more harm...